Local Institution - 0069

Barcelona 08208

1 studies enrolling now · 3 studies all time

What they study most

Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Pulmonary Fibrosis

Studies at this site

• A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation — Running, not enrolling
• Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis — Starting soon
• A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks — Completed